[The incidence and management of bone metastasis from breast cancer].
Mammary cancer is one of the solid malignancies, which easily metastasizes to bone. The frequency of bone metastases of breast cancer has been reported to be 65-75% of all breast cancer patients, and, in autopsy example at Shikoku Cancer Center, metastasis was recognized to be 74.7%. There are many symptomatic signs of bone metastases, but hypercalcemia needs to be treated immediately. Hypercalcemia might be diagnosed precisely because a lethal symptom appears. For diagnosis, bone scintigram, simple X-rays, MRI, and CT scan were effective. Radiotherapy, surgery, chemotherapy, and hormonal treatments were useful to improve the symptoms from bone metastasis; in addition, bisphosphonates demonstrated a synergistic effect with chemoendocrine treatments. Bisphosphonates also reduced the incidence of symptom-related events in patients with bone metastasis.
Saeki
Toshiaki
T
Dept. of Breast Oncology, Saitama Medical School.
Ookubo
Katsuhiko
K
Takeuchi
Hideki
H
Fujiuchi
Nobuko
N
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000473:pathology; D001943:Breast Neoplasms / Q000473:pathology*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D008279:Magnetic Resonance Imaging; D000077268:Pamidronate; D017410:Practice Guidelines as Topic; D011877:Radionuclide Imaging
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate